ORX

Orexo

Research update

Print

Orexo: Zubsolv Rx Data - March

The market share for Zubsolv (4-week rolling average) reached 5.42% (TRx) and 5.47% (quantity) at the end of March. After a weak start in 2017 the market share have stabilized in March, and begun to show some signs to a positive trend.

Growth in the overall market (buprenorphine/naloxone) continues to strengthen, and showed a y/y growth rate of 11.2% (TRx) and of 10.3% (quantity), on a monthly basis, at the end of March.

Continue reading (pdf) icon-download